• Explore /
  • Poster
  • / TiNivo-2: A phase 3, randomized, controlled, multicenter, open-label study to compare tivozanib in combination with nivolumab to tivozanib monotherapy in subjects with renal cell carcinoma who have progressed following one or two lines of therapy where one line has an immune checkpoint inhibitor.

TiNivo-2: A phase 3, randomized, controlled, multicenter, open-label study to compare tivozanib in combination with nivolumab to tivozanib monotherapy in subjects with renal cell carcinoma who have progressed following one or two lines of therapy where one line has an immune checkpoint inhibitor.

Abstract Poster

Authors

Toni Choueiri

Toni K. Choueiri

Dana-Farber Cancer Institute, Boston, MA

Toni K. Choueiri , Laurence Albiges , Rana R. McKay , Sumanta K. Pal , Hans J. Hammers , Daniel Yick Chin Heng , Katy Beckermann , Vijay Kasturi , Robert J. Motzer

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Genitourinary Cancer—Kidney and Bladder

Track

Genitourinary Cancer—Kidney and Bladder

Sub Track

Kidney Cancer

Clinical Trial Registration Number

NCT04987203

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr TPS4605)

DOI

10.1200/JCO.2022.40.16_suppl.TPS4605

Abstract #

TPS4605

Poster Bd #

92b

Abstract Disclosures

Similar Posters

First Author: Toni K. Choueiri

First Author: Douglas Adkins

First Author: Corinne Maurice-Dror

First Author: Sumanta K. Pal